Carboxyamidotriazole is a calcium channel blocker that blocks voltage-gated and ligand-gated calcium channels and has been investigated as an anti-cancer drug in vitro.[1][2]

References

  1. ^ Figg, W. D.; Cole, K. A.; Reed, E.; Steinberg, S. M.; Piscitelli, S. C.; Davis, P. A.; Soltis, M. J.; Jacob, J.; Boudoulas, S.; Goldspiel, B. (1995). "Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction". Clinical Cancer Research. 1 (8): 797–803. PMID 9816048.
  2. ^ Bonnefond, M. L.; Florent, R.; Lenoir, S.; Lambert, B.; Abeilard, E.; Giffard, F.; Louis, M. H.; Elie, N.; Briand, M.; Vivien, D.; Poulain, L.; Gauduchon, P.; n'Diaye, M. (2018). "Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BCLXL strategies through MCL-1 down-regulation". Oncotarget. 9 (74): 33896–33911. doi:10.18632/oncotarget.26084. PMC 6188062. PMID 30338034.